NCT06344936View on ClinicalTrials.gov

Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Chronic Kidney Disease(CKD)
Interventions
DRUG

HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules

Treatment PartⅠ: Itraconazole capsule, 200mg QD, 7 times; HRS-1780 tablets, 10mg QD, twice Treatment PartⅡ: Rifampicin capsules, 600mg QD, 14 times; HRS-1780 tablets, 10mg QD, twice

Trial Locations (1)

100730

Beijing Hospital, Beijing

All Listed Sponsors
lead

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY